Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 15/20 | 1.00 |
| ▸ | MMP2 | P08253 | 5/20 | 0.73 |
| ▸ | MMP13 | P45452 | 4/20 | 0.73 |
| ▸ | MMP14 | P50281 | 3/20 | 0.73 |
| ▸ | MMP7 | P09237 | 1/20 | 0.73 |
| ▸ | MMP12 | P39900 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12247612 | 1.00 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL12684680 | 1.00 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL20124798 | 0.92 | ADAMTS4 (0.86) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL3608574 | 0.89 | ADAMTS4 (0.80) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL13314510 | 0.89 | ADAMTS4 (0.80) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL1655209 | 0.88 | ADAMTS4 (0.78) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL1658625 | 0.87 | ADAMTS4 (0.76) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL12684636 | 0.85 | ADAMTS4 (0.73) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL1656904 | 0.84 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL3618624 | 0.84 | MMP2 (1.00) | ADAMTS4MMP2MMP13MMP14MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | claimed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | claimed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | claimed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | claimed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| EP-2681209-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | AQUILUS PHARMACEUTICALS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2681209-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | AQUILUS PHARMACEUTICALS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2681209-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | Aquilus Pharmaceuticals, Inc (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130338116-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | SUCHOLEIKI IRVING (US) | 2013-12-19 | — | — | US | disclosed |
| US-8530453-B2 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| WO-2012118498-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | AQUILUS PHARMACEUTICALS, INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20110230452-A1 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7390833-B2 | Method for treating ADAMTS-5-associated disease | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070225327-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7268135-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060004066-A1 | Method for treating ADAMTS-5-associated disease | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050130973-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130973-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | ADAMTS4 113/4885MMP2 5/4885MMP13 13/4885 |
| US-20060004066-A1 | Method for treating ADAMTS-5-associated disease | ADAMTS5, ADAMTS1, ADAMTS4 | ADAMTS4 3/4885MMP2 119/4885MMP13 34/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | ADAMTS4 113/4885MMP2 5/4885MMP13 13/4885 |
| US-20070225327-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | ADAMTS4 113/4885MMP2 5/4885MMP13 13/4885 |
| US-20130338116-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | MMP9, MMP10, MMP3 | ADAMTS4 28/4885MMP2 5/4885MMP13 8/4885 |
| US-20110230452-A1 | Compounds and methods for the treatment of pain and other diseases | MMP9, MMP10, MMP3 | ADAMTS4 28/4885MMP2 5/4885MMP13 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.